Country Information


Nigeria

 
HIV prevalence 15-49, 2007/2008 3.1%
Tuberculosis death rate 83/100,000 population
Malaria death rate (children under 5) 729/100,000 population
 
   
             
     
  With more than 130 million inhabitants, Nigeria is by far Africa's most populous nation. It is also a nation rich in petroleum and other natural resources; as much as 40 percent of Nigeria's GDP is derived from its oil industry. Declining oil prices over the last two decades, combined with macroeconomic mismanagement, have resulted in a sharp decline in Nigerian per capita income. Whereas in 1980 one-quarter of Nigerians lived in poverty, by 1996 two-thirds of Nigerians lived in poverty; over those same years per capita income fell dramatically.

Nigerian society is divided by language, ethnicity, and religion. While English is the official language, over 500 languages are currently spoken; most Nigerians speak Hausa (in the north), Yoruba (in the southwest), or Igbo (in the southeast). During 1967-1970 Nigeria experienced a bloody civil war as members of the Igbo ethnic group tried to establish a separate country. Currently the most significant division in Nigerian society lies between the the predominantly Muslim and Hausa speaking north, and the Christian south of the country. Shariah law has been proclaimed in many of Nigeria's northern states, and in the last couple of years tensions between Muslims and Christians have resulted in some isolated yet bloody clashes. Sporadic ethnic conflicts in the oil-rich delta region have also become a problem.

After 16 years of military rule (1983-1999), Nigeria has been holding elections and electing civilian leaders; President Umaru Masa Yar'adua took office in 2007, marking the first time a civilian has succeeded another civilian since independence. Foreign aid has risen in recent years, including support for programs like PEPFAR and the GFATM.

Not quite 6 percent of Nigeria's adult population is living with HIV or AIDS. This is low by Sub-Saharan standards, but even if the rate of infection does not increase Nigeria is predicted to suffer 4.3 million AIDS deaths by 2015; only South Africa is predicted to have higher AIDS mortality. As is the case in most countries, HIV prevalence rates are much higher in Nigeria's cities, and the HIV prevalence rate exceeds 10 percent in the Federal Capital Territory.

Nigeria is also a high-burden country for other communicable diseases. Malaria is endemic throughout Nigeria, and the WHO estimates the malaria mortality rate for children under five in Nigeria at 729 per 100,000. In April 2004 Nigeria's Minister of Health reported that his country spent over $1 billion annually in treating malaria, and that malaria was the cause behind one out of three deaths in children, and one out of ten deaths of pregnant women. He cited chloroquine resistance as a growing problem, owing in part to counterfeit drugs.

The annual incidence of tuberculosis is estimated at almost 300,000, and over 70,000 Nigerians die of that disease each year.

Sources: BBC country profile; DFID Country Assistance Plan; Synergy Project; AllAfrica.com, Daily Trust (Abuja), December 22, 2003; AllAfrica.com, Daily Trust (Abuja), April 28, 2004; United Nations Statistics Division; USAID in Nigeria

 
           
             
  The majority of health care in Nigeria is provided through the public sector, and is organized in a three-tiered system. The federal government develops policies and guidelines, provides funding and technical support, and monitors and evaluates implementation. The second tier of the system is organized at the level of the 36 states, and the third tier is at the level of the local government areas (LGAs). Although decentralization is a stated goal of the current health ministry, the States and LGAs primarily implement policies developed at the federal level.

Per capita expenditure on health is about $35 annually. In 2000 Nigeria devoted about 3.1 percent of its GDP on health (Source: WHO 2000, in Awaad, Brunegraber and Grimm); this marks a significant increase over health spending in the 1990s, when only 2 to 2.5 percent of GDP was spent on health (Stop TB Ministerial Conference in Amsterdam, March 2000).

On March 22, 2002, Nigeria launched a National Health Insurance Scheme (NHIS). Under this scheme workers contribute 5 percent of their salaries, with a 2-to-1 match from their employers, to an NHIS approved HMO. The HMO will then cover their health needs. Twice before Nigeria has attempted to launch an NHIS, so it remains to be seen if this launch will prove successful. Two cost-containment features limiting the value of NHIS are that it will not cover HIV/AIDS treatments, and it will not cover more than six members of any family. The latter restriction is expected to have greatest impact among Muslims.

In February 2001 Nigeria launched an ambitious HIV/AIDS Emergency Action Plan (HEAP). HEAP identifies over 200 actions to be implemented in the period 2001-2004, and the estimated cost of the program is $182 million. The national government of Nigeria has committed $54 million; IDA has committed $62 million, DFID $36 million, and USAID $22 million. Other donor agencies have committed smaller amounts as well. The national HIV-infection rate among adult TB patients was estimated to be about 27 percent in 2002.

In 2001, Nigeria developed a 2001-5 plan for TB control. In 2002 Fifty-five percent of Nigerians lived in an area where DOTS is implemented at the local level. The DOTS detection rate is only 11 percent, far below WHO objectives; the successful treatment rate is 79 percent. Implementation of DOTS is largely delivered through NGOs. The GDF is providing necessary TB drugs, but shortages of basic equipment, such as vehicles and microscopes, inhibit the Nigerian TB program. (Source: WHO Report 2004: Global Tuberculosis Control).

 
           
             
 
Total population. mid-2009 152.6 (millions)
HIV prevalence 15-49, 2007/2008 3.1%
Tuberculosis death rate 83/100,000 population
Prevalence of tuberculosis per 100,000 population, 2000 483
Prevalence of tuberculosis per 100,000 population, 2004 531
% Tuberculosis detection rate under DOTS, 2001 14
% Tuberculosis detection rate under DOTS, 2004 21
% Tuberculosis treatment success rate under DOTS, 2000 80
% Tuberculosis treatment success rate under DOTS, 2003 59
Malaria death rate (children under 5) 729/100,000 population
GNI PPP Per Capita, 2008 1,940 (US$)
Life expectancy at birth 47 years
Infant mortality rate 75/1,000 live births
Total fertility rate 5.7 per woman
Crude birth rate 41/1,000 population
Crude death rate 15/1,000 population
Adult male literacy level 91% (pct. 15+ literate)
Adult female literacy level 87% (pct. 15+ literate)
Contraceptive prevalence rate, modern methods 9% of women in union
Estimated number of people living with HIV: Adults and Children, 2005 2,900,000
Estimated number of people living with HIV: Adults and children, end 2003 3,600,000
Estimated number of people living with HIV: Adults and children, end 2001 3,400,000
Estimated number of people living with HIV: Adults (15+), 2005 2,600,000
Estimated number of people living with HIV: Adults (15-49), end 2003 3,300,000
Estimated number of people living with HIV: Adults (15-49), end 2001 3,100,000
Estimated number of people living with HIV: Adults (15-49) rate (%), 2005 5.4%
Estimated number of people living with HIV: Adults (15-49) rate (%), 2003 5.5%
Estimated number of people living with HIV: Women (15+), 2005 1,600,000
Estimated number of people living with HIV: Women 15-49, end 2003 1,900,000
Estimated number of people living with HIV: Women 15-49, end 2001 1,800,000
Estimated number of people living with HIV: Children (0-14), 2005 240,000
Estimated number of people living with HIV: Children (0-14), end 2003 290,000
Estimated number of people living with HIV: Children (0-14), end 2001 260,000
Estimated number of AIDS deaths: Adults and children, 2005 220,000
AIDS deaths in adults and children, end 2003 310,000
AIDS deaths in adults and children, end 2001 260,000
Estimated number of orphans due to AIDS: Children (0-17), 2005 930,000
Orphans due to AIDS (0-17), living 2003 1,800,000
Orphans due to AIDS (0-17), living 2001 1,300,000
% Women (15-49), currently married or living with a partner, who have ever discussed AIDS prevention with their husband or partner 36%

Demographic data contained in this section was obtained from the following sources: The Population Reference Bureau’s 2009 World Population Data Sheet was used for total population, life expectancy at birth, infant mortality, fertility, birth rate, death rate, % of married women 15-49 using modern methods of contraception, % of population 15-49 with HIV/AIDS in 2007/2008, and the GNI PPP per capita (2008). Literacy rates were found in the Population Reference Bureau’s publication 2005 Women of Our World. HIV prevalence data for 2001 and 2003 was obtained from the UNAIDS Barcelona 2002 report; HIV prevalence and orphan data for 2005 was obtained from the UNAIDS Report on the Global AIDS Epidemic 2006. Data on the % women who have discussed AIDS prevention with their husband or partner can be found in ORC Macro and USAID’s Women’s Lives and Experiences: Changes in the Past Ten Years (Research Findings from the Demographic and Health Surveys). Childhood malaria mortality data was accessed in 2003 from the United Nations Statistics Divisions’ Millennium Indicators. Tuberculosis data was obtained from the United Nations Statistics Division’s Millennium Indicators: MDGInfo 2006. In some cases information was unavailable.

 
           
             
  Nigeria has 18.5 physicians per 100,000 population, and 1.7 hospital beds per 1000 population. However, the bulk of these health resources are located in the southwestern corner of the country (Source: WHO/UNICEF Joint Programme on Mapping for Public Health). One consequence of this distribution of health resources can be seen in maternal mortality data: maternal mortality is 339 per 100,000 live births in the southwest, where the health infrastructure is strongest, and 1,716 in the northeast of the country.

In 2001 the Nigerian government allocated 64 billion Naira (approximately $580 million) to upgrading the facilities at eight of the country's teaching hospitals. These hospitals include: Port Harcourt, Enugu, Lagos, Ibadan, Maiduguri, Zaria, Ilorin and Jos. (Source: This Day Online, November 8, 2001)

Nigeria's pharmaceutical industry appears to be growing. Evans Medical PLC, a subsidiary of GlaxoSmithKline, is about to begin manufacturing ARV drugs in Nigeria. The company has been working with the WHO to approve its facility for good manufacturing practices (GMP) so that it can also export the ARV drugs to other African countries. Archy Pharmaceuticals, a company funded by Nigerian expatriates living in the US, is also about to begin production of ARV medications in Nigeria. (Sources: THISDAYOnLine.com; AllAfrica.com, Vanguard (lagos), July 29, 2004.)

 
           
             
 

Ahmadu Bello University Teaching Hospital

Contact Person: Professor I. Abdu-Aguye

Federal Medical Center

Contact person: Professor E. O. Otolorin, dipo.otolorin@anpa.net.ng

Nigerian Institute of Medical Research ( website )

NIMR comprises several laboratories, and houses the National HIV/AIDS Reference Library, opened in 2001. Its research priorities include studying the epidemiology of HIV/AIDS, tuberculosis, and malaria, and the study of the pharmacokinetics and the efficacy of anti-malarial drugs.

Nnamdi Azikiwe University

Nnamdi Azikiwe University, named after the first president of Nigeria, is located in Awka, a few kilometers away from the city of Enugu in the southeast of Nigeria. The University has a small Faculty of Medicine headed by Professor O .C. Ikpeze.

Obafemi Awolowo College of Health Sciences

The Ogun State Teaching Hospital (OSTH) is affiliated with Obafemi Awolowo College of Health Sciences.

Contact information for OSTH: osth@anpa.net.ng; 234-37-640121

University of Calabar, University of Calabar Teaching Hospital

In August 2004 the University of Calabar's Tropical Disease Research Center announced that it had developed a new and effective anti-malarial drug. No further information on this claim is available at this time.

The University of Calabar Teaching Hospital also has a strong program in cancer research.

Dr. Etetim Asuquo is the Chief Medical Director of the Teaching Hospital.

University of Ibadan, College of Medical Sciences ( website )

The University of Ibadan College of Medical Sciences has collaborated with the Multilateral Initiative on Malaria (MIM) on two recent research projects: a project to improve home management of childhood malaria; and a project to identify new anti-malarial drugs.

University of Ilorin Teaching Hospital

Contact person: Professor R. Fakeye; rfakeye@anpa.net.ng

University of Jos, Jos University Teaching Hospital ( website )

Jos University Teaching Hospital (JUTH) is a 530 bed facility. Research conducted at JUTH includes HIV and TB studies. JUTH is affiliated with US medical schools at Duke and the University of Utah, and is establishing an affiliation with Johns Hopkins.

JUTH has a shortage of staff, is short of equipment such as microscopes and computers, and is served by a poor telephone and transportation network.

For more information on JUTH, see its strategic plan.

University of Nigeria, College of Medicine

Contact person: Professor U. Megafu, megafu@com.unec.edu.ng

University of Port Harcourt Teaching Hospital

Contact person: Professor Mangete

With the institutions listed above, Nigeria's infrastructure for research includes a total of 16 medical schools. Contact information for these 16 schools can be found in the IIME Database.

 
           
             
 

Entity

Project Title

Diseases

Primary Category

Secondary Category

NIH West African HIV Drug Screening Capacity HIV/AIDS Drug Development  
  (Principal Investigator: Louis R. Barrows. 2001-2003.) This project will examine West African plants used in the treatment of AIDS for anti-HIV...

NIH Drug Development and Conservation of Biodiversity in West-central Africa HIV/AIDS,Malaria Drug Development  
  (PI: Brian Schuster. 1998-2003.) This project, directed by Colonel Brian Schuster of Walter Reed Army Hospital, is developing a series of 1-hectare...

NIH Nonparasitic Drug Discovery and Development Tuberculosis Drug Development  
  (PI: Brian Schuster. 2002) Colonel Brian Schuster of Walter Reed Army Hospital is leading this drug discovery effort aimed at developing...

NIH Love, Marriage and HIV: Gender and HIV Risk HIV/AIDS Epidemiology  
  (PI: Jennifer Hirsch. 2003-2007.) This is an international, multi-site ethnographic study of social and cultural determinants behind transmission of...

NIH Determinants of Drug Resistant Malaria in Nigeria Malaria Epidemiology Drug Development
  (PI: Dyann Wirth. 2004-2006.) Professor Wirth of Harvard University is leading this study of chloroquine and sulfadoxine-pyrimethamine resistant...

NIH Intraleukocytic Pigment as Prognostic Feature in Pediatric Falciparum Malaria Malaria Epidemiology  
  (PI: Peter Kremsner. 2002) Peter Kremsner of Michigan State University is directing this study which will examine ability to predict severity of...

NIH IHV/UM AITRP in the Caribbean, Brazil and Nigeria HIV/AIDS Capacity Drug Development,Epidemiology,Prevention
  (PI: William Blatner. 1998-2003.) The Institute of Human Virology and the University of Maryland is working with the University of Jos in Nigeria to...

Other US Cellulose Sulfate (CS) Gel and HIV in Nigeria HIV/AIDS Drug Development Prevention
  (Study Director: Vera Halpern, Family Health International. Nigeria PIs: Folasade Ogunsola, Lagos University; Orikomaba Obunge, University of...

Other US CDC HIV/AIDS Prevention Epidemiology
  CDC's Global AIDS Program (GAP) in Nigeria has concentrated on:
  • developing and disseminating behavior change communications
  • improving
...

Other US USAID HIV/AIDS,Malaria General  
  Following Nigeria's move from military rule to democratic governance, and former Secretary of State Madeleine Albright's identification of Nigeria...

International Trial of SAVVY Vaginal Gel and HIV in Nigeria HIV/AIDS Drug Development Prevention
  Biosyn, Family Health International, and United States Agency for International Development (Study chair: Paul Feldblum; PIs: Rasheed A. Bakare,...

International A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen HIV/AIDS Drug Development  
  (SECOND-LINE). The National Centre in HIV Epidemiology and Clinical Research, Merck, Abbott (Study Director: Mark A. Boyd. Study Chairs: David A...

International Chlorproguanil-Dapsone-Artesunate (CDA) Versus COARTEM for Uncomplicated Malaria Malaria Drug Development  
  GlaxoSmithKline, Medicines for Malaria Venture, WHO. The combination of chlorproguanil-dapsone-artesunate for the treatment of uncomplicated...

International Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) for Uncomplicated Malaria Malaria Drug Development  
  GlaxoSmithKline, Medicines for Malaria Venture, and World Health Organization. This phase III study of the efficacy and safety of a malaria...

International World Bank HIV/AIDS,Tuberculosis,Malaria General  
  The World Bank is providing two major loans to assist Nigeria in meeting the challenges posed by deadly communicable diseases.

The ...

International DFID (The United Kingdom) HIV/AIDS,Tuberculosis General  
  Like the United States, the United Kingdom has dramatically increased its bilateral aid for Nigeria in the last few years. In its most recent ...

International Global Fund for AIDS, Tuberculosis and Malaria (GFATM) HIV/AIDS,Malaria General  
  The Global Fund has approved funding for five projects in Nigeria, with a total financial commitment of more than $69 million in the two years. The...

International Japan HIV/AIDS,Tuberculosis,Malaria General  
  In 2002 Japan made a grant of ¥365 million to support UNICEF's Project for Infectious Disease Prevention for Children in Nigeria.

Source: ...

International Netherlands Leprosy Relief Association Tuberculosis General  
  The Netherlands Leprosy Relief Association (NSL) provides funding and support for DOTS implementation in four Nigerian states: Kaduna, Plateau,...

International CIDA (Canada) Tuberculosis General  
  In 2002 CIDA committed $11 million in aid to support DOTS programs in high-burden TB countries, including Nigeria, Zambia, Mali and The Gambia in...

International German Leprosy Relief Association Tuberculosis General  
  GLRA and KFW are supporting the DOTS anti-TB program in 14 of Nigeria's 36 states.

Source: ...

NGO MIM/TDR Grants for Malaria Research Malaria Epidemiology  
  A Mulitilateral Initiative on Malaria (MIM)/TDR Task Force awarded several grants for malaria research in Nigeria in 2002. Altogether the grants...

Foundation Gates Foundation HIV/AIDS Prevention  
  The Bill and Melinda Gates Foundation has provided a grant of $25 million to the Harvard School of Public Health for AIDS prevention work in...

Foundation The Damien Foundation Tuberculosis General  
  The Damien Foundation is fully supporting a DOTS program in two Nigerian states, Oyo and Osun.

Source: ...

 
           
             
 
  1. As mentioned above, Nigeria's HIV/AIDS Emergency Action Plan (HEAP), is a very ambitious multi-year program launched in early 2001. Actions listed on the HEAP timeline:
    • Training legal professionals
    • Advocating laws against sexual harrassment
    • Training community volunteers and alternative medicine workers
    • Conducting HIV and syphillis serosurveillance
    • Promoting condom access, including using police to sell
    ... additional information

  1. CDC's Global AIDS Program (GAP) has identified the following "Priorities for future action":
    • Developing a voluntary counseling and testing (VCT) program aimed at reducing mother to child transmission (MTCT).
    • Continuing involvement in behavior change communications, especially those targeted at youth and fiath-based organizations.
    • Monitoring the development of resistance to anti-retroviral drugs.

 
           



Home || HIV/AIDS || Tuberculosis || Malaria || Advanced Search || Links || Contact Us

Last site update: September 03, 2009

For questions, or to report problems with this site, please contact the Webmaster.

Disclaimer